Regulatory medical writers in the UK operate in a highly regulated pharmaceutical landscape where compliance is essential. At the heart of this system is the ABPI Code of Practice, which sets professional, ethical, and transparent standards for how pharmaceutical companies communicate internally and externally.

Even though many regulatory materials fall outside the direct scope of the Code, understanding its principles helps writers anticipate how content may later be adapted for promotional or public-facing use. A strong awareness of the Code supports cross-functional collaboration, reduces compliance risks, and strengthens the credibility of regulatory documents.

Decoding the Code

Developed by the Association of the British Pharmaceutical Industry, the ABPI Code of Practice governs how pharmaceutical companies in the UK promote medicines and interact with healthcare professionals, patients, and the public. It incorporates UK law and, in many areas, goes even further to ensure ethical, transparent, and responsible communication.

Key aspects of the ABPI Code:

• Ensures compliance with UK legislation and high industry standards
• Defines acceptable promotional activities and communication practices
• Guides ethical interactions with healthcare professionals and patient groups

Consequences of ABPI Code breaches:

• Financial penalties and formal sanctions
• Reputational damage for companies and brands
• Significant time and resources needed to respond to and defend allegations

The Prescription Medicines Code of Practice Authority (PMCPA), which administers the Code, reviews around 150 potential breach cases each year, highlighting the importance of proactive compliance.

Which regulatory materials are Code-relevant?

Most regulatory writing falls outside the ABPI Code due to its non-promotional nature and the heavily regulated environment.

Non-Code regulatory materials include:

• Clinical documentation for interventional studies
• Labelling, package inserts, and Summary of Product Characteristics (SmPCs)
• Information submitted to public bodies (e.g., NICE, AWMSG, SMC), provided it is factual, accurate, and not misleading

Regulatory materials that may fall under the ABPI Code include:

• Documentation for non-interventional studies, registries, and epidemiological research
• Contracts, study plans, supervision records, payments, ethics documents, and meeting notes
• Informed consent forms (ICFs) not approved by a Research Ethics Committee
• Clinical study reports (CSRs) shared externally
• Regulatory submission summaries sent to healthcare professionals
• Safety update reports or risk communication materials
• SmPCs or Patient Information Leaflets repurposed as Detail Aids for a salesperson
• Clinical trial lay summaries containing medicine-related information issued to the public

If distributed publicly or repurposed for promotional use, these materials must be balanced and clear, and include accurate risk/benefit information to avoid misleading the audience or influencing prescribing.

Social media considerations

With pharmaceutical communication becoming increasingly digital, the PMCPA monitors social media for potential ABPI Code breaches and has released social-media-specific guidance on how to avoid them.

Key points for writers:

• Engagement includes creating, liking, commenting, or sharing posts on either a professional or personal account
• Posts fall under the Code if they are promotional or if they involve a UK-based company or personnel (whether that be creating the post, featuring in it, or just engaging with it)
• Compliant, non-promotional posts include disease awareness, patient support, corporate news, clinical trial recruitment, or links to press releases
• Factual posts on therapy areas or drug classes are generally out of scope unless a specific medicine/company is identifiable (e.g., if it discusses the only medicine currently available in a particular therapy area)

Practical tips for compliance:

• Carefully review language, hashtags, account tags, images, and links for Code compliance before engaging
• Do not create or engage with posts that directly or indirectly discuss licensed medicines

Conclusion

Regulatory medical writers should:

1. Familiarise themselves with the ABPI Code to understand its purpose and practical implications
2. Always consider a document’s end use; non-promotional materials used for promotional purposes must comply with the Code
3. Engage with social media cautiously, ensuring that any engagement is not in violation of the ABPI Code.

By integrating Code awareness into daily practice, regulatory writers not only reduce compliance risks but also strengthen the integrity and credibility of their work.